Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of AD182 and AD504 in Obstructive Sleep Apnea
NCT04645524Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing AD182, AD504 and Placebo (3 arms). Primary endpoint: Apnea-Hypopnea Index. Started Dec 2020; status: completed.
02
Drugs
AD182atomoxetine + trazodone
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04645524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645524.